Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy

References

• Bunyavanich S, Rifas-Shiman SL, Platts-Mills TA, et al. Peanut allergy prevalence among school-age children in a US cohort not selected for any disease. J Allergy Clin Immunol. 2014;134(3):753–755.
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Severity of peanut allergy and the unmet gaps in care: a call to action. Am J Manag Care. 2018;24(19 suppl):S412–S418.
   PubMed Web of Science ®Google Scholar
• Gupta RS, Warren CM, Smith BM, et al. The public health impact of parent-reported childhood food allergies in the United States. Pediatrics. 2018;142(6):e20181235. doi: 10.1542/peds.2018-1235
   PubMed Web of Science ®Google Scholar
• Sicherer SH, Muñoz-Furlong A, Godbold JH, et al. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol. 2010;125(6):1322–1326. doi: 10.1016/j.jaci.2010.03.029
   PubMed Web of Science ®Google Scholar
• Peters RL, Allen KJ, Dharmage SC, et al. Natural history of peanut allergy and predictors of resolution in the first 4 years of life: a population-based assessment. J Allergy Clin Immunol. 2015;135(5):1257–1266.e1–2.
   Web of Science ®Google Scholar
• Peters RL, Guarnieri I, Tang MLK, et al. The natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study. J Allergy Clin Immunol. 2022;150(3):657–665.e13. doi: 10.1016/j.jaci.2022.04.008
   PubMed Web of Science ®Google Scholar
• Pavón-Romero GF, Parra-Vargas MI, Ramírez-Jiménez F, et al. Allergen immunotherapy: current and future trends. Cells. 2022;11(2):212. doi: 10.3390/cells11020212
   PubMed Web of Science ®Google Scholar
• Dioszeghy V, Mondoulet L, Dhelft V, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol. 2011;186(10):5629–5637. doi: 10.4049/jimmunol.1003134
   PubMed Web of Science ®Google Scholar
• Hervé PL, Dioszeghy V, Matthews K, et al. Recent advances in epicutaneous immunotherapy and potential applications in food allergy. Front Allergy. 2023 Oct 27;4:1290003. PMID: 37965375; PMCID: PMC10641725. In-depth review of the immunologic properties of the skin and data supporting the mechanism of action of epicutaneous immunotherapy for food allergy. doi: 10.3389/falgy.2023.1290003
   PubMedGoogle Scholar
• Mondoulet L, Dioszeghy V, Puteaux E, et al. Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Transl Allergy. 2012;2(1):22. doi: 10.1186/2045-7022-2-22
   PubMedGoogle Scholar
• Fleischer DM, Spergel JM, Kim EH, et al. Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy. Allergy Asthma Proc. 2020;41(4):278–284. doi: 10.2500/aap.2020.41.200045
   PubMed Web of Science ®Google Scholar
• Fleischer DM, Greenhawt M, Sussman G, et al. Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial. JAMA. 2019;321(10):946–955. doi: 10.1001/jama.2019.1113
   PubMed Web of Science ®Google Scholar
• Greenhawt M, Kim EH, Campbell DE, et al. Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years. J Allergy Clin Immunol Pract. 2020;8(9):3219–3221. doi: 10.1016/j.jaip.2020.05.030
   PubMed Web of Science ®Google Scholar
• Fleischer DM, Shreffler WG, Campbell DE, et al. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results. J Allergy Clin Immunol. 2020;146(4):863–874. doi: 10.1016/j.jaci.2020.06.028
   PubMed Web of Science ®Google Scholar
• Pongracic JA, Gagnon R, Sussman G, et al. Safety of epicutaneous immunotherapy in peanut-allergic children: REALISE randomized clinical trial results. J Allergy Clin Immunol Pract. 2022;10(7):1864–1873.e10. doi: 10.1016/j.jaip.2021.11.017
   PubMed Web of Science ®Google Scholar
• Greenhawt M, Sindher SB, Wang J, et al. Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy. N Engl J Med. 2023;388(19):1755–1766. doi: 10.1056/NEJMoa2212895
   PubMed Web of Science ®Google Scholar
• Baumert JL, Taylor SL, Koppelman SJ. Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy. J Allergy Clin Immunol Pract. 2018;6(2):457–465.e4. doi: 10.1016/j.jaip.2017.05.006
   PubMed Web of Science ®Google Scholar
• Remington BC, Krone T, Kim EH, et al. Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy. Ann Allergy Asthma Immunol. 2019;123(5):488–493.e2. doi: 10.1016/j.anai.2019.08.007
   PubMed Web of Science ®Google Scholar
• Remington BC, Blom WM, Bassa B, et al. Risk of shared equipment in restaurants for consumers with peanut allergy: a simulation for preparing Asian foods. Ann Allergy Asthma Immunol. 2020;125(5):543–551.e6. doi: 10.1016/j.anai.2020.07.030
   PubMed Web of Science ®Google Scholar
• Remington BC, Campbell DE, Green TD, et al. Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: relevance for exposure through restaurant meals. Ann Allergy Asthma Immunol. 2021;126(2):208–209. doi: 10.1016/j.anai.2020.11.015
   PubMed Web of Science ®Google Scholar
• Remington BC, Koppelman SJ, Green TD, et al. Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: a novel approach to assessing relevance. Allergy. 2021;76(10):3223–3226. doi: 10.1111/all.14973
   PubMed Web of Science ®Google Scholar
• Brown-Whitehorn TF, de Blay F, Spergel JM, et al. Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy. J Allergy Clin Immunol Pract. 2021;9(1):524–526. doi: 10.1016/j.jaip.2020.08.017
   PubMed Web of Science ®Google Scholar
• Sampson HA, Shreffler WG, Yang WH, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318(18):1798–1809. doi: 10.1001/jama.2017.16591
   PubMed Web of Science ®Google Scholar
• Loprinzi Brauer CE, Motosue MS, Li JT, et al. Prospective validation of the NIAID/FAAN criteria for emergency department diagnosis of anaphylaxis. J Allergy Clin Immunol Pract. 2016;4(6):1220–1226. doi: 10.1016/j.jaip.2016.06.003
   PubMed Web of Science ®Google Scholar
• Campbell RL, Hagan JB, Manivannan V, et al. Evaluation of national institute of allergy and infectious diseases/food allergy and anaphylaxis network criteria for the diagnosis of anaphylaxis in emergency department patients. J Allergy Clin Immunol. 2012;129(3):748–752. doi: 10.1016/j.jaci.2011.09.030
   PubMed Web of Science ®Google Scholar
• DunnGalvin A, Fleischer DM, Campbell DE, et al. Improvements in quality of life in children following epicutaneous immunotherapy (EPIT) for peanut allergy in the PEPITES and PEOPLE studies. J Allergy Clin Immunol Pract. 2021;9(1):216–224.e1. doi: 10.1016/j.jaip.2020.08.015
   PubMed Web of Science ®Google Scholar
• Togias A, Cooper SF, Acebal ML, et al. Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of allergy and Infectious Diseases–sponsored expert panel. Ann Allergy Asthma Immunol. 2017;118(2):166–173.e7. doi: 10.1016/j.anai.2016.10.004
   PubMed Web of Science ®Google Scholar
• Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 suppl):S1–S55.
   PubMed Web of Science ®Google Scholar
• Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. J Allergy Clin Immunol. 2010;126(6):1105–1118. doi: 10.1016/j.jaci.2010.10.008
   PubMed Web of Science ®Google Scholar
• Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and clinical immunology. Allergy. 2014;69(8):1026–1045. doi: 10.1111/all.12437
   PubMed Web of Science ®Google Scholar
• Alshajarah HA, Alghamdi HA, Alberi ZA, et al. Peanut-induced anaphylaxis in children: a literature review. Cureus. 2022;14(12):e32946. doi: 10.7759/cureus.32946
   PubMed Web of Science ®Google Scholar
• Avery NJ, King RM, Knight S, et al. Assessment of quality of life in children with peanut allergy. Pediatr Allergy Immunol. 2003;14(5):378–382. doi: 10.1034/j.1399-3038.2003.00072.x
   PubMed Web of Science ®Google Scholar
• Bollinger ME, Dahlquist LM, Mudd K, et al. The impact of food allergy on the daily activities of children and their families. Ann Allergy Asthma Immunol. 2006;96(3):415–421. doi: 10.1016/S1081-1206(10)60908-8
   PubMed Web of Science ®Google Scholar
• King RM, Knibb RC, Hourihane JO. Impact of peanut allergy on quality of life, stress and anxiety in the family. Allergy. 2009;64(3):461–468. doi: 10.1111/j.1398-9995.2008.01843.x
   PubMed Web of Science ®Google Scholar
• Primeau MN, Kagan R, Joseph L, et al. The psychological burden of peanut allergy as perceived by adults with peanut allergy and the parents of peanut-allergic children. Clin Exp Allergy. 2000;30(8):1135–1143.
   PubMed Web of Science ®Google Scholar
• Kim EH, Burks AW. Food allergy immunotherapy: oral immunotherapy and epicutaneous immunotherapy. Aller. 2020 Jun;75(6):1337–1346. doi: 10.1111/all.14220. Epub 2020 Feb 28. PMID: 32034781.
   PubMed Web of Science ®Google Scholar
• Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393(10187):2222–2232. doi: 10.1016/S0140-6736(19)30420-9
   PubMed Web of Science ®Google Scholar
• Anagnostou A. Weighing the benefits and risks of oral immunotherapy in clinical practice. Allergy Asthma Proc. 2021;42(2):118–123. doi: 10.2500/aap.2021.42.200107
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Palforzia: European public assessment report (EPAR): Authorisation Details; [first published 2020 Dec 21; updated 2022 Sep 19; cited 2022 Dec 2]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/palforzia#authorisation-details-section
   Google Scholar
• Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127(3):640–646.e1. doi: 10.1016/j.jaci.2010.12.1083
   PubMed Web of Science ®Google Scholar
• Kim EH, Bird JA, Keet CA, et al. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2023. S0091–S6749(23)01116–01118. doi: 10.1016/j.jaci.2023.08.032
   Web of Science ®Google Scholar
• Pfaar O, Bousquet J, Durham SR, et al. One hundred and ten years of allergen immunotherapy: a journey from empiric observation to evidence. Allergy. 2022;77(2):454–468. doi: 10.1111/all.15023
   PubMed Web of Science ®Google Scholar
• Senti G, Freiburghaus AU, Kundig TM. Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials. Curr Opin Allergy Clin Immunol. 2010;10(6):582–586. doi: 10.1097/ACI.0b013e32833f1419
   PubMed Web of Science ®Google Scholar
• Dupont C, Kalach N, Soulaines P, et al. Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125(5):1165–1167.
   PubMed Web of Science ®Google Scholar
• Spina L, Weisskopf M, von Moos S, et al. Comparison of microneedles and adhesive-tape stripping in skin preparation for epicutaneous allergen delivery. Int Arch Allergy Immunol. 2015;167(2):103–109. doi: 10.1159/000434681
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Nomoto Y, Watanabe M, et al. Application of microneedles to skin induces activation of epidermal Langerhans cells and dermal dendritic cells in mice. Biol Pharm Bull. 2016;39(8):1309–1318. doi: 10.1248/bpb.b16-00113
   PubMed Web of Science ®Google Scholar
• Clausen BE, Stoitzner P. Functional specialization of skin dendritic cell subsets in regulating T cell responses. Front Immunol. 2015;6:534. doi: 10.3389/fimmu.2015.00534
   PubMed Web of Science ®Google Scholar
• Mondoulet L, Dioszeghy V, Ligouis M, et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 2010;40(4):659–667. doi: 10.1111/j.1365-2222.2009.03430.x
   PubMed Web of Science ®Google Scholar
• Yu Y, Kiran Kumar MN, Wu MX. Delivery of allergen powder for safe and effective epicutaneous immunotherapy. J Allergy Clin Immunol. 2020;145(2):597–609. doi: 10.1016/j.jaci.2019.11.022
   PubMed Web of Science ®Google Scholar
• Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 2017;140(6):1485–1498. doi: 10.1016/j.jaci.2017.10.010
   PubMed Web of Science ®Google Scholar
• Del Duca E, Pavel AB, Dubin C, et al. Major differences in expression of inflammatory pathways in skin from different body sites of healthy individuals. J Invest Dermatol. 2019;139(10):2228–2232.e10. doi: 10.1016/j.jid.2019.04.008
   PubMed Web of Science ®Google Scholar
• Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, et al. Standardizing double-blind, placebo-controlled oral food challenges: american academy of allergy, asthma and immunology-european academy of allergy and clinical immunology PRACTALL consensus report. J Allergy Clin Immunol. 2012;130(6):1260–1274.
   PubMed Web of Science ®Google Scholar